BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20429630)

  • 1. Optimization and it's influence on value of doses in HDR and PDR brachytherapy.
    Skowronek J; Zwierzchowski G; Piotrowski T; Milecki P
    Neoplasma; 2010; 57(4):369-76. PubMed ID: 20429630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Values of biologically equivalent doses in healthy tissues: comparison of PDR and HDR brachytherapy techniques.
    Skowronek J; Malicki J; Piotrowski T
    Brachytherapy; 2010; 9(2):165-70. PubMed ID: 19879813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperfractionation of HDR brachytherapy - influence on doses and biologically equivalent doses in clinical target volume and healthy tissues.
    Skowronek J; Zwierzchowski G; Piotrowski T
    J Contemp Brachytherapy; 2009 Jun; 1(2):109-116. PubMed ID: 27795721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment planning for MRI assisted brachytherapy of gynecologic malignancies based on total dose constraints.
    Lang S; Kirisits C; Dimopoulos J; Georg D; Pötter R
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):619-27. PubMed ID: 17869676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.
    Pieters BR; van de Kamer JB; van Herten YR; van Wieringen N; D'Olieslager GM; van der Heide UA; Koning CC
    Radiother Oncol; 2008 Jul; 88(1):46-52. PubMed ID: 18378028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996-1999): a patterns of care study.
    Erickson B; Eifel P; Moughan J; Rownd J; Iarocci T; Owen J
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1083-92. PubMed ID: 16099599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose-rate and pulsed-dose-rate brachytherapy in palliative treatment of head and neck cancers.
    Bartochowska A; Wierzbicka M; Skowronek J; Leszczyńska M; Szyfter W
    Brachytherapy; 2012; 11(2):137-43. PubMed ID: 22104354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical comparison of two linear-quadratic model-based isoeffect fractionation schemes of high-dose-rate intracavitary brachytherapy for cervical cancer.
    Wang CJ; Huang EY; Sun LM; Chen HC; Fang FM; Hsu HC; Changchien CC; Leung SW
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):179-89. PubMed ID: 15093915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix.
    Leborgne F; Fowler JF; Leborgne JH; Zubizarreta E; Chappell R
    Radiat Oncol Investig; 1997; 5(6):289-99. PubMed ID: 9436246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of length of interval between pulses in PDR brachytherapy (PDRBT) on value of Biologically Equivalent Dose (BED) in healthy tissues.
    Skowronek J; Malicki J; Zwierzchowski G; Piotrowski T
    J Contemp Brachytherapy; 2010 Jun; 2(2):64-70. PubMed ID: 27829847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose-rate (HDR) or pulsed-dose-rate (PDR) perioperative interstitial intensity-modulated brachytherapy (IMBT) for local recurrences of previously irradiated breast or thoracic wall following breast cancer.
    Niehoff P; Dietrich J; Ostertag H; Schmid A; Kohr P; Kimmig B; Kovács G
    Strahlenther Onkol; 2006 Feb; 182(2):102-7. PubMed ID: 16447017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the appropriate fraction number and size of the HDR brachytherapy for cervical cancer.
    Liu WS; Yen SH; Chang CH; Yang KM; Wu YP; Chen KY
    Gynecol Oncol; 1996 Feb; 60(2):295-300. PubMed ID: 8631555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of PDR brachytherapy and external beam radiation therapy in the case of breast cancer.
    Teymournia L; Berger D; Kauer-Dorner D; Poljanc K; Seitz W; Aiginger H; Kirisits C
    Phys Med Biol; 2009 Apr; 54(8):2585-95. PubMed ID: 19349657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose-rate interstitial brachytherapy in recurrent and previously irradiated head and neck cancers--preliminary results.
    Narayana A; Cohen GN; Zaider M; Chan K; Lee N; Wong RJ; Boyle J; Shaha A; Kraus D; Shah J; Zelefsky MJ
    Brachytherapy; 2007; 6(2):157-63. PubMed ID: 17434110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose-rate brachytherapy in the treatment of recurrent and residual head and neck cancer.
    Glatzel M; Büntzel J; Schröder D; Küttner K; Fröhlich D
    Laryngoscope; 2002 Aug; 112(8 Pt 1):1366-71. PubMed ID: 12172246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MRI-guided 3D optimization significantly improves DVH parameters of pulsed-dose-rate brachytherapy in locally advanced cervical cancer.
    Lindegaard JC; Tanderup K; Nielsen SK; Haack S; Gelineck J
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):756-64. PubMed ID: 18191335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer.
    Pos FJ; Horenblas S; Lebesque J; Moonen L; Schneider C; Sminia P; Bartelink H
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):696-705. PubMed ID: 15183473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.